Highlights Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Market Closed - Nasdaq Other stock markets 03:59:48 2024-06-04 pm EDT			5-day change	1st Jan Change
25.79 ^USD	+1.74%		+4.16%	-12.64%

May. 31	Mirum Pharmaceuticals Gets Positive Opinion From EU Committee on Marketing Authorization for Livmarli to Treat PFIC	MT
May. 31	Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mirum Pharmaceuticals Gets Positive Opinion From EU Committee on Marketing Authorization for Livmarli to Treat PFIC	May. 31	MT
Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older	May. 31	CI
Mirum Pharmaceuticals, Inc. Reiterates Revenue Guidance for the Year 2024	May. 08	CI
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q1 Revenue $69.2M, vs. Street Est of $70.2M	May. 08	MT
Mirum Pharmaceuticals, Inc Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC	May. 07	CI
Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome	Apr. 02	CI
Mirum Pharmaceuticals Gets Additional FDA Approval for Livmarli	Mar. 13	DJ
US FDA approves expanded use of Mirum's liver disease drug	Mar. 13	RE
Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis	Mar. 13	CI
Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024	Feb. 28	CI
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q4 Revenue $69.6M, vs. Street Est of $67.9M	Feb. 28	MT
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023	Jan. 08	CI
Mirum Pharmaceuticals, Inc. Announces Data from EMBARK Phase 2b Study for Biliary Atresia	Dec. 18	CI
Mirum Pharmaceuticals, Inc. Presents New Data at the Liver Meeting	Nov. 13	CI
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q3 Revenue $47.7M, vs. Street Est of $38.6M	Nov. 02	MT
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Mirum Pharmaceuticals Says US FDA Extends Supplemental NDA Review for Livmarli to March 13; Shares Fall After Hours	23-10-17	MT
Mirum Pharmaceuticals, Inc. Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis	23-10-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Highlights

Filters